Wimi Bio

Wimi Biotechnology Co., Ltd. is a Chinese company founded in 2017 that focuses on precision breeding and biotechnology applications for major crops. The company, led by Chairman and CEO Dr. Jieting Xu, provides fee-for-service plant transformation and gene-editing services to agricultural research institutions and enterprises.

Wimi Bio has developed a high-throughput, genotype-independent genetic transformation platform for over 20 crops, including maize, rice, soybeans, and wheat. Its core technologies include an independently developed CAS12 enzyme, a universal genetic manipulation system, and high-volume gene editing capabilities. The company aims to improve crop traits such as insect and herbicide resistance, yield, and nutritional value. For instance, they have developed gene-edited maize with traits like high planting resistance and increased vitamin E. Beyond trait improvement, Wimi Bio is also using synthetic biology to develop functional products like dietary nutrients and oral edible vaccines.

The company serves over 1,000 institutions globally and utilizes a Laboratory Information Management System (LIMS) to ensure transparency and data integrity throughout the experimental process. In September 2024, Wimi Bio secured a Series A funding round of $14.1 million from investors including Changzhou Hi-tech Group and Sanya Yazhouwan Technology City Holding Group. The company has been recognized for its work, being named one of "China's 65 Most Socially Influential Startups in 2023" by Fortune China for its contributions to the seed industry and food security.

Keywords: gene editing, agricultural biotechnology, crop improvement, genetic transformation, precision breeding, plant transformation, agritech, crop science, molecular breeding, synthetic biology, CAS12, maize breeding, soybean technology, wheat genetics, plant biotechnology, crop traits, seed industry, food security, genetic engineering, herbicide resistance